## NXG Swiss Excellence

## NAV: CHF 120.65

Investment objective

ISIN: CH0382913793



Key features

· Concentrated portfolio of around 30 companies

Wealth Managers' investment committees.

The NXG Swiss Excellence Strategy focuses on shares of Swiss companies that reflect "Swiss Excellence"

worldwide as well as Swiss companies that are or are

expected to become Swiss leaders. The portfolio will be

rebalanced according to the global views of NextGen

- · Swiss Excellence played through three thematics
- · Actively managed portfolio

			JEI.
AMC data		2024	PTF
Quote	120.65		SLI
Share class currency	CHF	2023	PTF
AUM (CHF Mn)	11.9		SLI
Advisor	NextGen Wealth Managers SA	2022	PTF
Calculation Agent	Bank Vontobel AG, Zurich		SLI
ISIN	CH0382913793	2021	PTF
Valor	50670284		SLI
Benchmark	Swiss Leader Index (SLI)		
Issue date	31.08.2021	Stat	istics
Management fees	0.65%		
Administration fees	0.30%	Per	f. sinc
Quotation	Daily	Star	ndard
Subscription/redemption	Daily/daily	Max	x drav
Minimum investment	1 Certificate	Beta	а
Domicile	Switzerland	Nur	nber (
Dividend distribution	Capitalized	Avg	. mar

## Monthly comment

In June, Swiss equities slipped back into negative territory after a brief recovery in May. The large-cap SMI index fell by 2.5%, while small-cap stocks gained 2.9% and mid-cap stocks remained flat. Meanwhile, U.S. equities extended their strong rebound for a second month, driven by mega-cap and AI-focused tech companies.

The portfolio outperformed its benchmark, the Swiss Leader Index, declining by 1.3% compared to the benchmark's 1.7% drop. This brought year-to-date gains to 6.1% for the portfolio versus 2.1% for the benchmark. A key factor behind the monthly outperformance was our higher exposure to smaller companies. Strong stock selection in healthcare, materials, and industrials also contributed positively. However, performance was held back by our financial stock picks and an underweight position in information technology. During the month, we increased our holdings in Givaudan, Swiss Re, and Nestlé, and took profits on Galderma and Accelleron. We also raised our liquidity allocation, which now stands at 3.5%. Additionally, we received shares in Amrize through a spin-off from Holcim and have chosen to retain the position for now.

With volatility still elevated due to ongoing macroeconomic and geopolitical risks, we remain cautious as we move into the second half of the year.



6.3

-10

-1.8

-3.9

-3.5

-0.6

09

1.0

-7.5

-9.1

0.7

-2.6

-2.0

-4.4

-4.2

-1 1

-18

-2.2

-8.0

-7.4

-5 2

-33

-4 8

-5.1

5.0

6.1

31

2.9

04

1.1

5.9

5.3

07

64

5.5

4.2

4.2

-1 8

-1 2

26

3.5

-3.3

-3.5

54

ZUZI PIF	1.1				-5.2	3.1	-1.0	5.4
SLI	2.7				-6.1	3.9	-0.2	5.5
Statistics								
		PTF	SLI				PTF	SLI
Perf. since in	ception (%)	2.2	-2.8	Dividend yield %			2.8	3.0
Standard dev	viation p.a. (%)	8.7	10.3	P/E fwd 12m			17.9	18.6
Max drawdo	wn (%)	16.1	-17.3	P/CF fwd 12m			18.4	16.0
Beta		0.9		P/B fwd 12m			4.7	3.3
Number of p	ositions	27	30	Debt/equity			69	154
Avg. market	cap. (CHF Bn)	59	50	Return on Equity			20.0	14.3

Top positions						
	Name	Sector	Mkt. cap.	Weight		
1	Nestle SA	Consumer Staples	Large	7.4%		
2	Novartis AG	Health Care	Large	7.1%		
3	Roche Holding AG	Health Care	Large	6.8%		
4	UBS Group AG	Financials	Large	5.8%		
5	Swiss Re AG	Financials	Large	5.4%		
6	Lonza Group AG	Health Care	Large	5.1%		
7	Zurich Insurance Group AG	Financials	Large	4.7%		
8	ABB Ltd	Industrials	Large	4.5%		
9	Givaudan SA	Materials	Large	3.7%		
10	Alcon AG	Health Care	Large	3.7%		

## Contributors

79

124

8.3

-22.1

-20.7

1 1

1.9

7.8

7.6

-6.2

-5.6

3.1

03

0.0

-4.6

-2.6

3.1

19

-0.5

1.0

1.2

-4 4

22

1.5

-1.9

-2.6

Contributors			
Top contributors	Rel. contribution	Worst contributors	Rel. contribution
Accelleron Industries AG	0.4%	Nestle SA	-0.8%
Galderma Group AG	0.2%	Swiss Re AG	-0.3%
Novartis AG	0.2%	Givaudan SA	-0.3%
UBS Group AG	0.1%	Zurich Insurance Group AG	-0.2%
Sandoz Group AG	0.1%	Swissquote Group Holding SA	-0.2%

